The Coalition Against Major Diseases (CAMD) is a public-private partnership designed to creating new tools and methods that can be applied to increase the efficiency of the development process for new treatments for Alzheimer’s disease (AD) and related neurodegenerative diseases with impaired cognition and function. Professor Gallacher will present DPUK’s work ‘Deep Phenotyping of AD patients – Modelling Real World Evidence’ and will be part of the panel discussion on 'Global Synergies'.